Profile data is unavailable for this security.
About the company
Provectus Biopharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing immunotherapy medicines for different diseases that are based on a class of synthetic small-molecule immuno-catalysts called halogenated xanthenes (HXs). The Company’s lead molecule is named rose bengal sodium (RBS). The Company’s small molecule HX medical science platform comprises a range of different drug product candidates and preclinical pharmaceutical-grade RBS formulations using different concentrations and delivered by different routes of administration specific to each disease area and/or indication. The Company’s HX medical science platform includes clinical development programs in oncology, dermatology, and ophthalmology; in vivo proof-of-concept drug discovery programs in oncology, hematology, wound healing, and animal health, and in vitro drug discovery programs in infectious diseases and tissue regeneration and repair.
- Revenue in USD (TTM)683.90k
- Net income in USD-2.79m
- Incorporated2013
- Employees4.00
- LocationProvectus Biopharmaceuticals Inc800 S. Gay Street, Suite 1610KNOXVILLE 37929United StatesUSA
- Phone+1 (865) 769-4011
- Fax+1 (302) 674-5266
- Websitehttps://www.provectusbio.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Lantern Pharma Inc | 0.00 | -17.75m | 40.15m | 21.00 | -- | 1.30 | -- | -- | -1.65 | -1.65 | 0.00 | 2.87 | 0.00 | -- | -- | 0.00 | -40.79 | -28.83 | -44.71 | -30.17 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -11.93 | -- | -- | -- |
Estrella Immunopharma Inc | 0.00 | -6.29m | 40.17m | -- | -- | 9.43 | -- | -- | -0.1687 | -0.1687 | 0.00 | 0.1178 | 0.00 | -- | -- | -- | -168.15 | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 34.21 | -- | -- | -- |
OncoCyte Corp | 1.02m | -36.80m | 40.26m | 43.00 | -- | 1.77 | -- | 39.35 | -4.26 | -4.26 | 0.1087 | 1.70 | 0.0126 | -- | 1.14 | 23,790.70 | -44.55 | -35.11 | -49.04 | -39.71 | 8.11 | -- | -3,532.75 | -2,373.36 | -- | -154.75 | 0.0212 | -- | 56.89 | -- | -34.84 | -- | 55.41 | -- |
Clene Inc. | 442.00k | -30.46m | 40.34m | 82.00 | -- | -- | -- | 91.26 | -4.74 | -4.74 | 0.0688 | -0.0783 | 0.0082 | 1.89 | 5.49 | 5,390.24 | -56.31 | -39.43 | -81.90 | -47.32 | 81.00 | -- | -6,890.50 | -5,261.20 | 0.993 | -16.96 | 1.02 | -- | 38.27 | -- | -65.47 | -- | -- | -- |
Calcimedica Inc | 0.00 | -12.59m | 42.57m | 14.00 | -- | 3.08 | -- | -- | -1.88 | -1.88 | 0.00 | 1.29 | 0.00 | -- | -- | 0.00 | -60.97 | -63.99 | -75.48 | -72.71 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 3.51 | -- | -44.35 | -- |
vTv Therapeutics Inc | 1.00m | -20.18m | 43.08m | 16.00 | -- | 2.61 | -- | 43.08 | -6.81 | -6.81 | 0.2701 | 5.47 | 0.029 | -- | 6.54 | 62,500.00 | -73.77 | -111.84 | -170.69 | -- | -- | -- | -2,540.90 | -680.94 | -- | -- | 0.00 | -- | -100.00 | -- | -5.67 | -- | -- | -- |
HST Global Inc | 0.00 | -123.45k | 43.22m | 1.00 | -- | -- | -- | -- | -0.0209 | -0.0209 | 0.00 | -0.0004 | 0.00 | -- | -- | -- | -3,300.80 | -5,836.01 | -- | -- | -- | -- | -- | -- | -- | -27.31 | 5.81 | -- | -- | -- | -0.7858 | -- | -- | -- |
Atara Biotherapeutics Inc | 62.39m | -181.05m | 43.72m | 165.00 | -- | -- | -- | 0.7008 | -39.90 | -39.90 | 13.06 | -22.61 | 0.343 | 0.931 | 42.60 | 277,275.60 | -99.55 | -70.20 | -256.98 | -86.94 | 80.14 | -- | -290.20 | -1,559.33 | 0.2945 | -250.76 | -- | -- | -86.51 | -- | -20.95 | -- | -49.14 | -- |
Provectus Biopharmaceuticals Inc | 683.90k | -2.79m | 44.09m | 4.00 | -- | -- | -- | 64.47 | -0.0067 | -0.0067 | 0.0016 | -0.0179 | 0.5379 | -- | 613.36 | 170,975.00 | -219.43 | -276.33 | -- | -- | -- | -- | -407.97 | -1,667.76 | -- | -9.75 | -- | -- | -43.61 | -- | 12.74 | -- | -- | -- |
LAVA Therapeutics NV | 7.40m | -24.18m | 44.43m | 37.00 | -- | 1.04 | -- | 6.01 | -0.8976 | -0.8976 | 0.2741 | 1.63 | 0.0689 | -- | 3.23 | 199,946.00 | -22.51 | -- | -27.11 | -- | 97.78 | -- | -326.89 | -- | -- | -- | 0.1257 | -- | -65.09 | -- | -31.55 | -- | -- | -- |
Rallybio Corp | 299.00k | -73.88m | 46.88m | 43.00 | -- | 0.5859 | -- | 156.79 | -1.79 | -1.79 | 0.0072 | 1.93 | 0.0025 | -- | -- | 6,953.49 | -61.57 | -- | -67.23 | -- | -- | -- | -24,709.37 | -- | -- | -- | 0.00 | -- | -- | -- | -11.87 | -- | -- | -- |
Vor Biopharma Inc | 0.00 | -118.09m | 47.20m | 168.00 | -- | 0.481 | -- | -- | -1.74 | -1.74 | 0.00 | 1.43 | 0.00 | -- | -- | 0.00 | -60.16 | -45.79 | -64.52 | -48.98 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -27.98 | -- | -- | -- |
Inotiv Inc | 501.06m | -99.22m | 48.11m | 1.96k | -- | 0.2642 | -- | 0.096 | -3.84 | -3.84 | 19.44 | 7.00 | 0.615 | 8.12 | 6.83 | 256,297.70 | -12.11 | -23.84 | -19.28 | -29.26 | 24.93 | 29.31 | -19.70 | -33.24 | 0.2279 | -0.6234 | 0.6774 | -- | 4.52 | 85.10 | 68.80 | -- | 83.64 | -- |
Holder | Shares | % Held |
---|---|---|
Home Federal Bank of Tennessee (Investment Management)as of 30 Jun 2024 | 100.00k | 0.02% |
Lee, Danner & Bass, Inc.as of 30 Jun 2024 | 50.00k | 0.01% |
Atlas Wealth LLCas of 30 Jun 2024 | 26.62k | 0.01% |
LBMC Investment Advisors LLCas of 30 Jun 2024 | 22.00k | 0.01% |
Academy Capital Management, Inc.as of 30 Jun 2024 | 20.00k | 0.01% |
Financal Symmetry, Inc.as of 30 Jun 2024 | 10.19k | 0.00% |
Huntington National Bank (Investment Management)as of 30 Jun 2024 | 1.00 | 0.00% |